id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2020-N-1440-0012,FDA,FDA-2020-N-1440,Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,Notice,Advisory Committee,2021-05-14T04:00:00Z,2021,5,2021-05-14T04:00:00Z,2021-06-24T03:59:59Z,2021-06-11T01:00:12Z,2021-10181,0,0,0900006484affd6d
FDA-2020-N-1440-0003,FDA,FDA-2020-N-1440,"Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a 
Public Docket; Request for Comments",Notice,Request for Comments,2021-03-12T05:00:00Z,2021,3,2021-03-12T05:00:00Z,2021-04-27T03:59:59Z,2021-04-28T01:00:26Z,2021-05202,0,0,0900006484a68e54
FDA-2020-N-1440-0001,FDA,FDA-2020-N-1440,Oncologic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,Notice,Request for Comments,2020-12-28T05:00:00Z,2020,12,2020-12-28T05:00:00Z,2021-02-09T04:59:59Z,2021-02-10T02:00:46Z,2020-28558,0,0,09000064849cc88e